Indication | Research | Preclinical | Phase I | Phase II | Phase III | |
---|---|---|---|---|---|---|
CKD-943**
- Opioid Receptor Kappa agonist
|
Pain, Uremic pruritus | |||||
CKD-516
- Tublin Polymerization inhibitor
|
Colorectal cancer | |||||
CKD-581
- Pan-HDAC inhibitor
|
Multiple myeloma | |||||
CKD-506 - HDAC6 inhibitor |
Autoimmune disease | |||||
CKD-504 - HDAC6 inhibitor |
Huntington’s disease | |||||
CKD-508 - CETP inhibitor |
Dyslipidemia | |||||
CKD-510 - HDAC6 inhibitor |
Rare disease |
CKD-943** : License-in from Cara Therapeutics in the US
Indication | Research | Preclinical | Phase I | Phase II | Phase III | |
---|---|---|---|---|---|---|
CKD-11101 - NESP/ARANESP Biosimilar (2nd generation of EPO) |
Anemia(Abroad) | |||||
CKD-701 - Lucentis Biosimilar |
AMD | |||||
CKD-702 - Bispecific antibody |
Cancer | |||||
CKD-971*
- IFN-alpha kinoid
|
Lupus |
Indication | Research | Preclinical | Phase I | Phase II | Phase III | |
---|---|---|---|---|---|---|
CKD-398 |
Diabetes | |||||
CKD-391 |
Dyslipidemia | |||||
CKD-386 |
Dyslipidemia/Hypertension | |||||
CKD-841 - Sustained release injection |
Cancer | |||||
CKD-396 |
Diabetes | |||||
CKD-333 |
Dyslipidemia/Hypertension | |||||
CKD-351 |
Glaucoma | |||||
CKD-491 |
Periodontitis | |||||
CKD-497 |
Bronchitis | |||||
CKD-495 |
Gastritis | |||||
CKD-385 |
Hypertension/Heart failure/Angina pectoris |